Drug Use Investigation of Somatropin for GHD-ADULTS
Information source: Pfizer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dwarfism, Growth Hormone Deficiency
Intervention: Somatropin (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
Post marketing drug use investigation of Genotropin for GHD-ADULTS.
Clinical Details
Official title: Drug Use Investigation of GENOTROPIN for GHD-ADULTS
Study design: Case-Only, Prospective
Primary outcome: Factors considered to affect the safety and/or efficacy of this drug.The incidence of adverse drug reactions. The number of adverse drug reactions not expected from the LPD (unknown adverse drug reactions).
Secondary outcome: This study is a non-interventional/observational study and does not have any secondary outcomes measures.
Detailed description:
All the patients whom an investigator prescribes the first Somatropin should be registered
consecutively until the number of subjects reaches target number.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
The patients who were administered Somatropin to treat "Adult growth hormone deficiency
(limited to severe type)".
Exclusion Criteria:
Patients not administerd Somatropin.
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: March 2007
Ending date: June 2009
Last updated: January 26, 2008
|
